Director, Biostatistics, Pulmovant
pulmovant
- Remote · United States
- Remote
- Director/Executive
- Posted
Responsibilities
- program, including protocol development, statistical analysis plans (SAPs), and sample size/power calculations
- Partner with Clinical Development and Regulatory on trial design decisions, including endpoint selection and interim analysis strategy
- Oversee CRO/vendor biostatistics deliverables, ensuring quality and timeline adherence
- Lead statistical input for regulatory submissions (e.g., NDA/BLA), including responses to health authority queries
- Collaborate with Data Management on CRF design, database structure, and data quality standards
- to internal leadership and external stakeholders (e.g., DSMBs, advisory boards)
- Mentor junior biostatistics staff or contractors as the function scales
Contribute to departmental
- initiatives,
- readiness.
Roivant (Nasdaq
ROIV) is a commercial-stage biopharmaceutical company that aims to improve the lives of patients by accelerating the development and commercialization of medicines that matter. Roivant’s pipeline includes LISRAYA™ (brepocitinib), a potent small molecule inhibitor of JAK1 and TYK2 FDA-approved for the treatment of dermatomyositis in adult patients and also in late-stage development for the treatment of non-infectious uveitis, cutaneous sarcoidosis and lichen planopilaris; IMVT-1402, a fully human monoclonal antibody targeting FcRn in development across several IgG-mediated autoimmune indications; and mosliciguat, an inhaled sGC activator in development for pulmonary hypertension associated with interstitial lung disease. We advance our pipeline by creating nimble subsidiaries or “Vants” to develop and commercialize our medicines and technologies. For more information, visit www.roivant.com
Position
Director, Biostatistics
Summary
Pulmovant is seeking a Director of Biostatistics to serve as lead biostatistician for its Phase 3 PHrontier program evaluating mosliciguat in pulmonary hypertension associated with interstitial lung disease (PH-ILD). This role will drive statistical strategy for the pivotal trial, partnering closely with Clinical Development, Regulatory, and Data Management to ensure rigorous, submission-ready trial design and analysis. The ideal candidate brings direct experience taking a program through Phase 3 and toward regulatory filing.
Key
Duties and Responsibilities
- Serve as lead biostatistician for
- Pulmovant's
- Phase 3
PHrontier
Present statistical results and methodology standards, process improvements, talent development, resource planning, and inspection
Education and Experience
- PhD or MS in Biostatistics, Statistics, or related field
- 8+ years of biostatistics experience in clinical drug development, including direct Phase 3 experience
- Prior experience contributing to a regulatory submission (NDA/BLA) strongly preferred
- Pulmonary/respiratory therapeutic area experience a plus
Essential Skills and Abilities
- Deep expertise in SAS and/or R for clinical trial analysis
- Strong understanding of ICH/FDA statistical guidance and GCP, ICH standards, and CDISC principles
Experience managing CRO biostatistics relationships
Excellent cross-functional communication skills, able to translate statistical findings for non-statistician stakeholders
Comfortable operating in a lean, scaling clinical-stage environment
Pulmovant provides equal employment opportunities to all employees and applicants for employment and prohibits discrimination and harassment of any type without regard to race, color, religion, age, sex, national origin, disability status, genetics, protected veteran status, sexual orientation, gender identity or expression, or any other characteristic protected by federal, state or local laws.
We will not accept unsolicited resumes nor outreach from agencies. Please do not send agency resumes to our website or Roivant Sciences and affiliated employees. Thanks!
